Stock Update (NASDAQ:CRIS): Curis, Inc. Announces Presentation of Data from CUDC-427 and IRAK-4 Programs at AACR Annual Meeting

Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 18 – 22, 2015 in Philadelphia.

Curis researchers will present data for its proprietary targeted cancer drug candidate, CUDC-427, an oral antagonist of inhibitor of apoptosis or IAP proteins. Curis’ collaborator, Aurigene will present data from their interleukin-1 receptor association kinase-4, or IRAK-4, inhibitor program. (Original Source)

Shares of Curis Inc. closed today at $2.77, down $0.08 or 2.81%. CRIS has a 1-year high of $3.50 and a 1-year low of $1.09. The stock’s 50-day moving average is $2.84 and its 200-day moving average is $1.90.

On the ratings front, Curis has been the subject of a number of recent research reports. In a report issued on January 28, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on CRIS, with a price target of $6, which implies an upside of 109% from current levels. Separately, on January 21, Cowen’s Boris Peaker reiterated a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Boris Peaker have a total average return of 14.9% and 40.4% respectively. Pantginis has a success rate of 56.8% and is ranked #62 out of 3572 analysts, while Peaker has a success rate of 67.0% and is ranked #21.

In total, 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $2.87 which is 39.4% above where the stock opened today.

Curis Inc is abiotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its products includeCUDC-907,phosphatidylinositol-3-kinase andsmall molecule inhibitor of histone deacetylase.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts